| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 123.0 | 83.5 |
| Gross profit | 87.1 | 58.4 |
| Profit before tax | 17.4 | 5.6 |
| Net income | 17.4 | 5.7 |
| EPS (diluted, $ a share) | $0.32 | $0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +204.5% |
|---|---|
| Revenue, year on year | +47.2% |
| Gross margin | 70.9% |
| Operating margin | 9.0% |
10-Q filed with the SEC, NASDAQ: BLLN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BillionToOne, Inc.: key numbers
- Share price
- $96.31Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BillionToOne, Inc.
All →BillionToOne SVP of Laboratory Operations Bosch John Roderick ten Sells $321K of Stock
Bosch John Roderick ten, SVP of Laboratory Operations, sold 2,834 shares of BillionToOne, Inc. at $113.17 a share, worth $321K in total on Nov 2, 2026. Shares held after the trade: 16,551 (-7.9%).
- Value
- $321K
- Shares
- 2,834
- Average price
- $113.17
- Role
- SVP of Laboratory Operations
- Holding change
- -7.9%
- Trade date
- Nov 2, 2026
BillionToOne Chairman and CEO Oguzhan Atay Sells $3.33M of Stock
Oguzhan Atay, Chairman and CEO, sold 30,335 shares of BillionToOne, Inc. at $107.31 to $113.17 a share (average $109.93) in 14 transactions, worth $3.33M in total on Nov 2, 2026. Shares held after the trade: 141,167 (-1.9%).
- Value
- $3.33M
- Shares
- 30,335
- Average price
- $109.93
- Role
- Chairman and CEO
- Holding change
- -1.9%
- Trade date
- Nov 2, 2026
BillionToOne CTO David Tsao Sells $2.18M of Stock
David Tsao, CTO, sold 19,977 shares of BillionToOne, Inc. at $107.31 to $113.17 a share (average $109.24) in 13 transactions, worth $2.18M in total on Nov 2, 2026. Shares held after the trade: 1,023 (-16.9%).
- Value
- $2.18M
- Shares
- 19,977
- Average price
- $109.24
- Role
- CTO
- Holding change
- -16.9%
- Trade date
- Nov 2, 2026
BillionToOne Financial Results
BillionToOne reported Q3 2026 revenue of $123.0 million, a 47% increase year-over-year, driven by strong growth in both prenatal and oncology clinical testing. The company maintained GAAP profitability with $11.0 million in operating income and raised its full-year 2026 revenue guidance to a range of $460 million to $470 million.
- Term
- Q3 2026
“Our third quarter was another period of strong execution. We delivered rapid growth with continued GAAP profitability, and more clinicians are choosing our tests in both prenatal and oncology.”
Dr. Oguzhan Atay, Co-Founder and CEO
BillionToOne Chairman and CEO Oguzhan Atay Sells $1.3M of Stock
Oguzhan Atay, Chairman and CEO, sold 11,000 shares of BillionToOne, Inc. at $118.00 a share, worth $1.3M in total on Oct 28, 2026. Shares held after the trade: 146,501 (-1.8%).
- Value
- $1.3M
- Shares
- 11,000
- Average price
- $118.00
- Role
- Chairman and CEO
- Holding change
- -1.8%
- Trade date
- Oct 28, 2026
BillionToOne Chairman and CEO Oguzhan Atay Sells $1.08M of Stock
Oguzhan Atay, Chairman and CEO, sold 10,900 shares of BillionToOne, Inc. at $98.00 to $102.78 a share (average $99.14) in 7 transactions, worth $1.08M in total between Oct 14, 2026 and Oct 15, 2026. Shares held after the trade: 149,168 (-1.8%).
- Value
- $1.08M
- Shares
- 10,900
- Average price
- $99.14
- Role
- Chairman and CEO
- Holding change
- -1.8%
- Trade date
- Oct 14, 2026 to Oct 15, 2026